CS203080B2 - Method of preparing the imping agent against the influenza,containing the weakened h3 n2 strain of inflenza virus - Google Patents

Method of preparing the imping agent against the influenza,containing the weakened h3 n2 strain of inflenza virus Download PDF

Info

Publication number: CS203080B2
Authority: CS; Czechoslovakia
Prior art keywords: serum; strain; influenza; virus; influenza virus
Prior art date: 1973-09-27

Application number

CS746552A

Other languages

Czech (cs)

English (en)

Inventor

Julien Peotermans

Original Assignee

Rit Rech Ind Therapeut

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1973-09-27

Filing date

1974-09-24

Publication date

1981-02-27

1974-09-24 Application filed by Rit Rech Ind Therapeut filed Critical Rit Rech Ind Therapeut

1981-02-27 Publication of CS203080B2 publication Critical patent/CS203080B2/cs

Links

238000000034 method Methods 0.000 title claims abstract description 16
241000700605 Viruses Species 0.000 title claims description 43
206010022000 influenza Diseases 0.000 title description 6
210000002966 serum Anatomy 0.000 claims abstract description 64
241000712461 unidentified influenza virus Species 0.000 claims abstract description 48
239000003112 inhibitor Substances 0.000 claims abstract description 36
238000010790 dilution Methods 0.000 claims abstract description 19
239000012895 dilution Substances 0.000 claims abstract description 19
229960003971 influenza vaccine Drugs 0.000 claims abstract description 16
235000013601 eggs Nutrition 0.000 claims abstract description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 7
241000700199 Cavia porcellus Species 0.000 claims description 11
230000003612 virological effect Effects 0.000 claims description 6
239000000463 material Substances 0.000 claims description 5
239000011780 sodium chloride Substances 0.000 claims description 5
210000001161 mammalian embryo Anatomy 0.000 claims description 4
244000052616 bacterial pathogen Species 0.000 claims description 3
241000700198 Cavia Species 0.000 claims description 2
230000000644 propagated effect Effects 0.000 claims 1
229960005486 vaccine Drugs 0.000 abstract description 19
241000287828 Gallus gallus Species 0.000 abstract description 14
239000000203 mixture Substances 0.000 abstract description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
239000008024 pharmaceutical diluent Substances 0.000 abstract description 2
238000007865 diluting Methods 0.000 abstract 1
239000007923 nasal drop Substances 0.000 abstract 1
229940100662 nasal drops Drugs 0.000 abstract 1
239000007922 nasal spray Substances 0.000 abstract 1
229940097496 nasal spray Drugs 0.000 abstract 1
210000002257 embryonic structure Anatomy 0.000 description 14
241000283073 Equus caballus Species 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
238000011081 inoculation Methods 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
241000282339 Mustela Species 0.000 description 6
230000035931 haemagglutination Effects 0.000 description 6
239000002054 inoculum Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000001888 Peptone Substances 0.000 description 5
108010080698 Peptones Proteins 0.000 description 5
239000012530 fluid Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
235000019319 peptone Nutrition 0.000 description 5
238000001727 in vivo Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000002255 vaccination Methods 0.000 description 4
244000309464 bull Species 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000000694 effects Effects 0.000 description 3
229960001226 live attenuated influenza Drugs 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
238000005215 recombination Methods 0.000 description 3
230000006798 recombination Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
241000271566 Aves Species 0.000 description 2
239000003708 ampul Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
229940099472 immunoglobulin a Drugs 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000036512 infertility Effects 0.000 description 2
210000003800 pharynx Anatomy 0.000 description 2
244000144977 poultry Species 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000012360 testing method Methods 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
229940124873 Influenza virus vaccine Drugs 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000037797 influenza A Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Virology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CS746552A 1973-09-27 1974-09-24 Method of preparing the imping agent against the influenza,containing the weakened h3 n2 strain of inflenza virus CS203080B2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US05/401,335 US3953592A (en)	1973-09-27	1973-09-27	Live influenza virus vaccines and preparation thereof

Publications (1)

Publication Number	Publication Date
CS203080B2 true CS203080B2 (en)	1981-02-27

Family

ID=23587327

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS746552A CS203080B2 (en)	1973-09-27	1974-09-24	Method of preparing the imping agent against the influenza,containing the weakened h3 n2 strain of inflenza virus

Country Status (22)

Country	Link
US (1)	US3953592A (de)
JP (1)	JPS5058223A (de)
AT (1)	AT331978B (de)
BE (1)	BE819865A (de)
CA (1)	CA1030450A (de)
CH (1)	CH595447A5 (de)
CS (1)	CS203080B2 (de)
DD (1)	DD114966A5 (de)
DE (1)	DE2445819A1 (de)
DK (1)	DK508274A (de)
ES (1)	ES430415A1 (de)
FI (1)	FI278774A (de)
FR (1)	FR2245376B1 (de)
GB (1)	GB1461188A (de)
HU (1)	HU169383B (de)
IE (1)	IE40180B1 (de)
IL (1)	IL45589A (de)
LU (1)	LU70998A1 (de)
NL (1)	NL7411746A (de)
NO (1)	NO743433L (de)
SE (1)	SE429405B (de)
ZA (1)	ZA745571B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6042209B2 (ja) *	1974-05-31	1985-09-20	北里研究所（社団法人）	インフルエンザウイルスの新鮮分離株を発育鶏卵へ短期間で順化させる方法
US4318903A (en) *	1978-07-12	1982-03-09	Smithkline-Rit	Live influenza virus vaccine and the preparation thereof
US4278662A (en) *	1979-10-16	1981-07-14	Smith Kline - Rit	Attenuated influenza type A virus vaccine
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
US4783411A (en) *	1984-10-22	1988-11-08	Janis Gabliks	Influenza-A virus vaccine from fish cell cultures
NZ224422A (en) *	1987-05-05	1990-11-27	Molecular Eng Ass	Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US7678087B2 (en) *	1999-09-29	2010-03-16	Heska Corporation	Equine intranasal delivery system
US6398774B1 (en)	1999-09-29	2002-06-04	Heska Corporation	Intranasal delivery system
EP2411049B1 (de)	2009-03-27	2020-01-15	Academia Sinica	Verfahren und zusammensetzungen zur immunisierung gegen viren
TWI537385B (zh)	2010-11-04	2016-06-11	中央研究院	產生具簡單醣基化之表面蛋白質之病毒顆粒的方法

1973
- 1973-09-27 US US05/401,335 patent/US3953592A/en not_active Expired - Lifetime
1974
- 1974-08-28 CH CH1173374A patent/CH595447A5/xx not_active IP Right Cessation
- 1974-08-29 CA CA208,125A patent/CA1030450A/en not_active Expired
- 1974-08-30 ZA ZA00745571A patent/ZA745571B/xx unknown
- 1974-09-04 IL IL45589A patent/IL45589A/en unknown
- 1974-09-04 NL NL7411746A patent/NL7411746A/xx not_active Application Discontinuation
- 1974-09-13 FR FR7431029A patent/FR2245376B1/fr not_active Expired
- 1974-09-13 BE BE148474A patent/BE819865A/xx not_active IP Right Cessation
- 1974-09-21 JP JP49109440A patent/JPS5058223A/ja active Pending
- 1974-09-24 CS CS746552A patent/CS203080B2/cs unknown
- 1974-09-24 NO NO743433A patent/NO743433L/no unknown
- 1974-09-25 DE DE19742445819 patent/DE2445819A1/de not_active Ceased
- 1974-09-25 FI FI2787/74A patent/FI278774A/fi unknown
- 1974-09-25 LU LU70998A patent/LU70998A1/xx unknown
- 1974-09-26 SE SE7412113A patent/SE429405B/sv unknown
- 1974-09-26 HU HURE565A patent/HU169383B/hu unknown
- 1974-09-26 IE IE1994/74A patent/IE40180B1/xx unknown
- 1974-09-26 AT AT776074A patent/AT331978B/de active
- 1974-09-26 GB GB4184974A patent/GB1461188A/en not_active Expired
- 1974-09-26 ES ES430415A patent/ES430415A1/es not_active Expired
- 1974-09-26 DK DK508274A patent/DK508274A/da unknown
- 1974-09-26 DD DD181344A patent/DD114966A5/xx unknown

Also Published As

Publication number	Publication date
NO743433L (de)	1975-04-28
LU70998A1 (de)	1975-03-06
SE7412113L (de)	1975-04-01
SE429405B (sv)	1983-09-05
ATA776074A (de)	1975-12-15
IE40180L (en)	1975-03-27
FR2245376B1 (de)	1978-07-28
DD114966A5 (de)	1975-09-05
ES430415A1 (es)	1977-02-01
CA1030450A (en)	1978-05-02
US3953592A (en)	1976-04-27
GB1461188A (en)	1977-01-13
HU169383B (de)	1976-11-28
DE2445819A1 (de)	1975-04-10
DK508274A (de)	1975-06-02
AU7330674A (en)	1976-03-18
IL45589A (en)	1977-05-31
ZA745571B (en)	1975-09-24
IE40180B1 (en)	1979-03-28
BE819865A (fr)	1975-03-13
AT331978B (de)	1976-09-10
FI278774A (de)	1975-03-28
FR2245376A1 (de)	1975-04-25
CH595447A5 (de)	1978-02-15
NL7411746A (nl)	1975-04-02
IL45589A0 (en)	1974-11-29
JPS5058223A (de)	1975-05-21

Publication	Publication Date	Title
US6635246B1 (en)	2003-10-21	Inactivated influenza virus vaccine for nasal or oral application
Reynolds et al.	2000	Protective immunity against Newcastle disease: the role of antibodies specific to Newcastle disease virus polypeptides
JP2849632B2 (ja)	1999-01-20	ワクチン製剤
US10905756B2 (en)	2021-02-02	Bivalent swine influenza virus vaccine
US4693893A (en)	1987-09-15	Vaccines for equine influenza
Webster et al.	1996	Immunity to Mexican H5N2 avian influenza viruses induced by a fowl pox-H5 recombinant
Pensaert et al.	1994	Vaccination of chickens against a Belgian nephropathogenic strain of infectious bronchitis virus B1648 using attenuated homologous and heterologous strains
Patnayak et al.	2002	Experimental and field evaluation of a live vaccine against avian pneumovirus
Wareing et al.	2001	Immunogenic and isotype‐specific responses to russian and US cold‐adapted influenza a vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice
CS203080B2 (en)	1981-02-27	Method of preparing the imping agent against the influenza,containing the weakened h3 n2 strain of inflenza virus
Greenbaum et al.	2002	Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine
Cursiefen et al.	1979	Evaluation of a vaccine against infectious bursal disease in field trials
Hofstad	1967	Immunity following aerosol exposure to high-embryo-passage avian infectious bronchitis virus
Webster et al.	1986	Vaccination as a strategy to reduce the emergence of amantadine-and rimantadine-resistant strains of A/Chick/Pennsylvania/83 (H5N2) influenza virus
Isaka et al.	2008	Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice
Daly et al.	2007	Equine influenza vaccine containing older H3N8 strains offers protection against A/eq/South Africa/4/03 (H3N8) strain in a short‐term vaccine efficacy study
CA1152895A (en)	1983-08-30	Process for the preparation of novel influenza virus strains and influenza virus vaccines containing them
CN101524537A (zh)	2009-09-09	流感口服含片疫苗、流感口服缓释疫苗以及二者制备方法
TW200927928A (en)	2009-07-01	Inactivated influenza vaccine
Avtushenko et al.	1996	Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization
US3962423A (en)	1976-06-08	Live influenza type B virus vaccines and preparation thereof
Webster et al.	1993	Efficacy of equine influenza vaccines for protection against A/Equine/Jilin/89 (H3N8)—a new equine influenza virus
KR101669142B1 (ko)	2016-10-25	안약형 백신의 신규 아쥬반트
KR101626798B1 (ko)	2016-06-02	신규한 h3n2 혈청형의 인플루엔자 바이러스 및 이를 포함하는 백신 조성물
JP4785531B2 (ja)	2011-10-05	マーカーワクチンとしてのニューカッスル病ウイルスのエスケープミュータント